Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/14/2023 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (Right to Buy) | 25k | $1.57 | $39.2k | | 06/14/2023 |
06/01/2023 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 13.9k | $0.00 | $0 | | 06/01/2023 |
06/01/2023 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 27.8k | $1.11 | $30.8k | | 06/01/2023 |
05/24/2023 | Arbutus Biopharma Corp | ABUS | Grant | Stock Option (Right to Buy) | 55k | $0.00 | $0 | | 05/24/2023 |
06/15/2022 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (Right to Buy) | 25k | $1.72 | $43k | | 06/15/2022 |
06/16/2021 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (Right to Buy) | 20k | $7.13 | $142.6k | | 06/16/2021 |
06/03/2021 | Arbutus Biopharma Corp | ABUS | Grant | Stock Options | 22k | $0.00 | $0 | | 06/03/2021 |
02/25/2021 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 8.2k | $0.00 | $0 | | 02/25/2021 |
02/25/2021 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 16.4k | $11.19 | $183.5k | | 02/25/2021 |
06/17/2020 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (Right to Buy) | 20k | $8.35 | $167k | | 06/17/2020 |
05/28/2020 | Arbutus Biopharma Corp | ABUS | Grant | Stock Options | 22k | $0.00 | $0 | | 05/28/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 15k | $10.46 | $156.9k | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 2.5k | $0.00 | $0 | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 10k | $0.00 | $0 | | 05/18/2020 |
05/18/2020 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 20k | $10.46 | $209.2k | | 05/18/2020 |
11/22/2019 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Common Stock | 5k | $0.00 | $0 | | 11/22/2019 |
11/22/2019 | SANGAMO THERAPEUTICS, INC | SGMO | Grant | Stock Option (Right to Buy) | 30k | $9.81 | $294.3k | | 11/22/2019 |
08/17/2019 | Arbutus Biopharma Corp | ABUS | Grant | Stock Options | 22k | $0.00 | $0 | | 08/17/2019 |
06/19/2019 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (Right to Buy) | 14k | $11.31 | $158.3k | | 06/19/2019 |
12/20/2018 | CytomX Therapeutics, Inc. | CTMX | Grant | Stock Option (right to buy) | 28k | $14.04 | $393.1k | | 12/20/2018 |
10/18/2018 | Arbutus Biopharma Corp | ABUS | Grant | Director Share Option (Right to Buy) | 44k | $4.71 | $207.2k | | 10/18/2018 |
02/21/2018 | GILEAD SCIENCES, INC. | GILD | Grant | Common Stock | 4.8k | $0.00 | $0 | | 02/15/2018 |
02/21/2018 | GILEAD SCIENCES, INC. | GILD | Grant | Common Stock | 1.6k | $0.00 | $0 | | 02/15/2018 |
02/21/2018 | GILEAD SCIENCES, INC. | GILD | Payment of Exercise | Common Stock | 1.6k | $80.69 | $132.9k | | 02/15/2018 |
02/21/2018 | GILEAD SCIENCES, INC. | GILD | Gift | Common Stock | 2.3k | $0.00 | $0 | | 02/15/2018 |
02/21/2018 | GILEAD SCIENCES, INC. | GILD | Gift | Common Stock | 2.3k | $0.00 | $0 | By Trust | 02/15/2018 |
02/15/2018 | GILEAD SCIENCES, INC. | GILD | Grant | Common Stock | 221 | $62.35 | $13.8k | | 02/15/2018 |
02/01/2018 | GILEAD SCIENCES, INC. | GILD | Grant | Non-qualified Stock Option (Right to Buy) | 75.5k | $83.49 | $6.3M | | 02/01/2018 |
01/16/2018 | GILEAD SCIENCES, INC. | GILD | Sale | Common Stock | 75.2k | $80.00 | $6M | | 01/16/2018 |
01/16/2018 | GILEAD SCIENCES, INC. | GILD | Sale | Common Stock | 24.8k | $80.99 | $2M | | 01/16/2018 |
01/16/2018 | GILEAD SCIENCES, INC. | GILD | Exercise | Non-qualified Stock Option (Right to Buy) | 100k | $21.58 | $2.2M | | 01/16/2018 |
11/09/2017 | GILEAD SCIENCES, INC. | GILD | Grant | Common Stock | 2.7k | $0.00 | $0 | | 11/09/2017 |
11/09/2017 | GILEAD SCIENCES, INC. | GILD | Payment of Exercise | Common Stock | 1.4k | $73.02 | $100.3k | | 11/09/2017 |
11/09/2017 | GILEAD SCIENCES, INC. | GILD | Gift | Common Stock | 1.3k | $0.00 | $0 | | 11/09/2017 |
11/09/2017 | GILEAD SCIENCES, INC. | GILD | Gift | Common Stock | 1.3k | $0.00 | $0 | By Trust | 11/09/2017 |
|